Nonclinical Safety Services and Regulatory Strategy for Clinical Development

BlueRidge Life Sciences Nonclinical Safety helps pharmaceutical and biotech clients design, manage, and optimize nonclinical programs with the scientific rigor and regulatory foresight needed to move safely and efficiently toward clinical trials. Our team supports more than 30 therapeutic areas and modalities, including traditional small molecules, biologics, cell and gene therapies, and rare disease treatments.

Strategic Regulatory Guidance and Program Design

We guide clients through early development with precision, foresight, and confidence. To achieve this, we develop integrated toxicology strategies tailored to indication, route, and patient population. Our experts identify appropriate study models and address challenges such as species selection — including programs with no relevant species. Furthermore, we facilitate regulatory meetings and guide toxicology response strategies across FDA, EMA, Health Canada, Australia, New Zealand, and MHRA.

We provide strategic regulatory guidance and document review throughout development. This includes the preparation of nonclinical sections for INDs, CTAs, NDAs, BLAs, and CTDs, as well as contributing to 70+ INDs/CTAs submitted since 2012.

Study Oversight and Clinical Integration

We oversee critical GLP and non-GLP studies and translate results into actionable insights, seamlessly integrating them into early-phase clinical development strategies to drive informed, accelerated decision-making. Our team helps to manage a wide variety of studies ranging from in vitro toxicology to general toxicology to reproductive and developmental to carcinogenicity and more.

Key objectives of our oversight include:

• Guide clinical dose selection, escalation strategies, and clinical monitoring plans
• Ensure alignment between nonclinical strategy and clinical program goals
• Represent toxicology in cross-functional development discussions and at regulatory meetings
• Develop tabulated and narrative summaries for pharmacokinetics and toxicology

Flexible Approaches for Rare Disease Programs

For rare and serious conditions, nonclinical safety programs often require customized approaches. BlueRidge helps clients align with regulatory guidance that allows shortened or reduced toxicology packages and establishes First-in-Human doses. We help navigate pediatric requirements, including justification for deferring or omitting juvenile toxicity studies when appropriate, and address global differences in requirements for rare disease indications.

Data-Driven Risk Assessment and Modeling

We drive smarter, earlier decision-making through risk-informed assessments and advanced predictive tools. Our team helps clients prepare carcinogenicity and reproductive toxicity assessments and develop monographs for excipients and impurities. We assess metabolite safety to meet regulatory thresholds and use (Q)SAR models like Derek Nexus, Leadscope, and Meteor to justify waivers and streamline regulatory submissions with data-backed evidence.

Advanced Safety Assessment of ADCs and Biologics

The clinical development of Antibody-Drug Conjugates (ADCs) remains challenged by notable safety concerns, which can not only hinder progress but also lead to the withdrawal of approved drugs. To address these issues, we support an integrated analysis of non-clinical and clinical safety data from marketed ADCs. This approach systematically evaluates the role of each ADC component—antibody, linker, and payload—in mediating both on-target and off-target toxicities. This safety evaluation platform is compliant with international GLP standards and has demonstrated significant advantages in the evaluation of biologics, including antibody drugs, cell and gene therapies.

Scope of Product and Therapeutic Expertise

• Routes of Administration: Intravenous, subcutaneous, intrathecal, inhalation, dermal, oral and more.
• Product Types: Traditional drugs, botanicals, peptides, oligonucleotides, antibodies, ADCs, biosimilars, fusion proteins, bispecifics, vaccines, and immunotherapies.
• Therapeutic Areas: Oncology, neurology, ophthalmology, autoimmune disease, metabolic disorders, cardiovascular, and rare diseases.

Our experience spans a diverse portfolio of therapeutic modalities and indications, reflecting the depth and versatility of our nonclinical safety expertise to help you reduce risk and move forward with confidence.